Coya Therapeutics Inc. (COYA)
5.55
-0.10 (-1.77%)
At close: Jan 15, 2025, 12:48 PM
undefined% (undefined)
| Bid | 5.55 |
| Market Cap | 92.73M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.65 |
| PE Ratio (ttm) | -8.54 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 5.69 |
| Volume | 46,184 |
| Avg. Volume (20D) | 94,936 |
| Open | 5.72 |
| Previous Close | 5.65 |
| Day's Range | 5.51 - 5.89 |
| 52-Week Range | 4.75 - 10.69 |
| Beta | undefined |
About COYA
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial f...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 29, 2022
Employees 8
Stock Exchange NASDAQ
Ticker Symbol COYA
Website https://www.coyatherapeutics.com
Analyst Forecast
According to 4 analyst ratings, the average rating for COYA stock is "Buy." The 12-month stock price forecast is $16.5, which is an increase of 197.30% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
2 months ago ·
Source
-27.67%
Coya Therapeutics shares are trading lower. The co...
Unlock content with
Pro Subscription
2 months ago ·
Source
+13.73%
Coya Therapeutics shares are trading higher after the company announced it will report results from an investigator-initiated Phase 2 trial of low-dose interleukin-2 in patients with mild-to-moderate Alzheimer's disease.
